JP2022505378A5 - - Google Patents

Info

Publication number
JP2022505378A5
JP2022505378A5 JP2021521380A JP2021521380A JP2022505378A5 JP 2022505378 A5 JP2022505378 A5 JP 2022505378A5 JP 2021521380 A JP2021521380 A JP 2021521380A JP 2021521380 A JP2021521380 A JP 2021521380A JP 2022505378 A5 JP2022505378 A5 JP 2022505378A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
therapeutic agent
lipid
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021521380A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022505378A (ja
JP7477844B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/056186 external-priority patent/WO2020081485A1/en
Publication of JP2022505378A publication Critical patent/JP2022505378A/ja
Publication of JP2022505378A5 publication Critical patent/JP2022505378A5/ja
Application granted granted Critical
Publication of JP7477844B2 publication Critical patent/JP7477844B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021521380A 2018-10-17 2019-10-15 免疫調節剤を含む徐放性医薬組成物およびその使用 Active JP7477844B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862746810P 2018-10-17 2018-10-17
US62/746,810 2018-10-17
PCT/US2019/056186 WO2020081485A1 (en) 2018-10-17 2019-10-15 Sustained-release pharmaceutical compositions comprising an immunomodulating agent and uses thereof

Publications (3)

Publication Number Publication Date
JP2022505378A JP2022505378A (ja) 2022-01-14
JP2022505378A5 true JP2022505378A5 (enExample) 2022-09-12
JP7477844B2 JP7477844B2 (ja) 2024-05-02

Family

ID=70284157

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021521380A Active JP7477844B2 (ja) 2018-10-17 2019-10-15 免疫調節剤を含む徐放性医薬組成物およびその使用

Country Status (6)

Country Link
US (1) US12274785B2 (enExample)
EP (1) EP3866764A4 (enExample)
JP (1) JP7477844B2 (enExample)
CN (1) CN113015520A (enExample)
TW (1) TWI767149B (enExample)
WO (1) WO2020081485A1 (enExample)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL91664A (en) * 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
LT3173073T (lt) 2004-05-03 2025-01-10 Ipsen Biopharm Ltd. Liposomos, skirtos vaistų pristatymui
CN101199505B (zh) * 2007-12-20 2012-05-23 沈阳药科大学 维拉帕米脂质体及其制备方法
CN101756902B (zh) * 2008-12-23 2011-10-05 上海医药工业研究院 一种可乐定多囊脂质体及其制备方法
CN101601654B (zh) * 2009-07-03 2010-08-18 王明 盐酸法舒地尔脂质体注射剂及其新应用
CN102406606B (zh) * 2011-11-29 2013-01-23 海南美大制药有限公司 富马酸喹硫平脂质体固体制剂
US20150157610A1 (en) * 2012-05-23 2015-06-11 Osaka University Pharmaceutical composition for treating inflammatory disease
EP2968145A1 (en) * 2013-03-13 2016-01-20 Mallinckrodt LLC Modified docetaxel liposome formulations
ES2777223T3 (es) * 2013-03-15 2020-08-04 Taiwan Liposome Co Ltd Composición de liposoma para liberación controlada de fármaco
CN106999419A (zh) * 2014-08-04 2017-08-01 佐尼奥尼制药股份有限公司 远程装载略微水溶性药物至脂质膜泡
WO2016191547A1 (en) * 2015-05-26 2016-12-01 Comfort Care For Animals Llc Liposome loading
EP4218739A3 (en) * 2016-01-08 2023-08-09 The Regents of The University of California Mesoporous silica nanoparticles with lipid bilayer coating for cargo delivery
MX2018008507A (es) * 2016-01-11 2019-07-04 Merrimack Pharmaceuticals Inc Inhibición de proteína relacionada con ataxia telangiectasia y rad3 (atr).
WO2019082139A1 (en) * 2017-10-27 2019-05-02 Shilpa Medicare Limited LIPOSOMAL FINGOLIMOD HYDROCHLORIDE INJECTION
CN108354904A (zh) * 2018-05-21 2018-08-03 天津双硕医药科技有限公司 一种含有盐酸金刚烷胺的口服药物组合物
WO2020023445A1 (en) * 2018-07-24 2020-01-30 Taiwan Liposome Co., Ltd. Sustained-release pharmaceutical compositions comprising a therapeutic agent for treating dementia and uses thereof

Similar Documents

Publication Publication Date Title
US10028911B2 (en) Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent
JP2013526545A5 (enExample)
JP2019023243A5 (enExample)
JP2022500398A5 (enExample)
RU2014120216A (ru) Комбинационные липосомальные композиции для лечения рака
FI3821887T3 (fi) Mitoksantroni liposomin käyttö ei-hodgkinin lymfooman hoitoon
CA2739822A1 (en) Liposomal systems comprising sphingomyelin
JP2024542099A5 (enExample)
CN102612372B (zh) 用于快速治疗外耳炎的方法和组合物
JP2016513651A5 (enExample)
JP2023531666A5 (enExample)
TWI767133B (zh) 含有治療憂鬱症或焦慮症之治療劑的緩釋組合物及其用途
TWI755629B (zh) 含鎮靜藥物之緩釋藥物組合物及其用途
IL299155B1 (en) Oxazolidinone compounds, liposome compositions comprising oxazolidinone compounds and methods of use thereof
FI3790554T3 (fi) Lääkekoostumus treprostiniilin säädeltyä vapautumista varten
JP2022505378A5 (enExample)
JP2022527638A5 (enExample)
Nardo et al. In vivo assessment of triazine lipid nanoparticles as transfection agents for plasmid DNA
TW202143978A (zh) 格列本脲脂質體組合物及其製備方法
Velebny et al. Toxocara canis in mice: effect of stabilised liposomes on the larvicidal efficacy of fenbendazole and albendazole
TWI767149B (zh) 含有免疫調節劑的緩釋藥物組合物及其用途
BR102020022824A2 (pt) Composição, composição farmacêutica, uso de uma composição tópica estável compreendendo uma nanoemulsão, e de pelo menos um composto antileishmanial, e, método para o tratamento de leishmaniose cutânea
WO2025172284A1 (en) Lipids for nanoparticle delivery platform
RU2021132189A (ru) Фармацевтическая композиция слабокислотного лекарственного средства и способы применения
RU2019132446A (ru) Соединения и композиции для внутриклеточной доставки терапевтических агентов